NASDAQ:ENTA - Enanta Pharmaceuticals Stock Price, Forecast & News

Enanta Pharmaceuticals trades on the NASDAQ under the ticker symbol "ENTA."

Enanta Pharmaceuticals Inc (NASDAQ:ENTA) issued its quarterly earnings data on Thursday, February, 6th. The biotechnology company reported $0.65 earnings per share for the quarter, topping the consensus estimate of $0.59 by $0.06. The biotechnology company earned $52.57 million during the quarter, compared to analysts' expectations of $58.75 million. Enanta Pharmaceuticals had a net margin of 18.00% and a return on equity of 7.39%. The business's revenue was down 24.8% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.25 EPS. View Enanta Pharmaceuticals' Earnings History.

Enanta Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, May 5th 2020. View Earnings Estimates for Enanta Pharmaceuticals.

4 equities research analysts have issued 12 month price objectives for Enanta Pharmaceuticals' shares. Their forecasts range from $57.00 to $130.00. On average, they expect Enanta Pharmaceuticals' stock price to reach $101.33 in the next twelve months. This suggests a possible upside of 95.3% from the stock's current price. View Analyst Price Targets for Enanta Pharmaceuticals.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Enanta Pharmaceuticals in the last year. There are currently 1 sell rating, 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Enanta Pharmaceuticals.

Media headlines about ENTA stock have been trending somewhat positive this week, according to InfoTrie. The research group scores the sentiment of press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Enanta Pharmaceuticals earned a coverage optimism score of 1.8 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Enanta Pharmaceuticals.

Some companies that are related to Enanta Pharmaceuticals include Nektar Therapeutics (NKTR), FibroGen (FGEN), GW Pharmaceuticals PLC- (GWPH), HUTCHISON CHINA/S (HCM), Mirati Therapeutics (MRTX), Blueprint Medicines (BPMC), PTC Therapeutics (PTCT), Ultragenyx Pharmaceutical (RARE), SAGE Therapeutics (SAGE), Zai Lab (ZLAB), Emergent Biosolutions (EBS), Myokardia (MYOK), Allakos (ALLK), Apellis Pharmaceuticals (APLS) and Axsome Therapeutics (AXSM).

Based on aggregate information from My MarketBeat watchlists, some companies that other Enanta Pharmaceuticals investors own include Verizon Communications (VZ), HCA Healthcare (HCA), Pandora Media (P), Ryder System (R), Tandem Diabetes Care (TNDM), NVIDIA (NVDA), Wells Fargo & Co (WFC), Ford Motor (F), Alibaba Group (BABA) and Tesla (TSLA).

Enanta Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Farallon Capital Management LLC (8.83%), State Street Corp (4.19%), Renaissance Technologies LLC (3.69%), Acadian Asset Management LLC (1.74%), Goldman Sachs Group Inc. (1.68%) and Bank of New York Mellon Corp (0.95%). Company insiders that own Enanta Pharmaceuticals stock include Bruce L A Carter, George Golumbeski, Jay R Luly, Nathalie Adda, Nathaniel S Gardiner, Paul J Mellett, Tim Ocain and Yat Sun Or. View Institutional Ownership Trends for Enanta Pharmaceuticals.

ENTA stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, FMR LLC, Marshall Wace North America L.P., Baird Financial Group Inc., AQR Capital Management LLC, Rafferty Asset Management LLC, UBS Group AG and Thrivent Financial for Lutherans. Company insiders that have sold Enanta Pharmaceuticals company stock in the last year include Bruce L A Carter, George Golumbeski, Paul J Mellett and Yat Sun Or. View Insider Buying and Selling for Enanta Pharmaceuticals.

ENTA stock was bought by a variety of institutional investors in the last quarter, including Farallon Capital Management LLC, Fairmount Funds Management LLC, Renaissance Technologies LLC, Goldman Sachs Group Inc., Prudential Financial Inc., California Public Employees Retirement System, AJO LP and Aviva PLC. View Insider Buying and Selling for Enanta Pharmaceuticals.

Shares of ENTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ENTA stock can currently be purchased for approximately $51.89.

Enanta Pharmaceuticals has a market capitalization of $1.03 billion and generates $205.20 million in revenue each year. The biotechnology company earns $46.38 million in net income (profit) each year or $2.21 on an earnings per share basis. Enanta Pharmaceuticals employs 113 workers across the globe.View Additional Information About Enanta Pharmaceuticals.

The official website for Enanta Pharmaceuticals is http://www.enanta.com/.

Enanta Pharmaceuticals' mailing address is 500 ARSENAL STREET, WATERTOWN MA, 02472. The biotechnology company can be reached via phone at 617-607-0800 or via email at [email protected]